Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.059 USD | +11.43% | +26.17% | +107.57% |
May. 06 | Oppenheimer Upgrades Chemomab Therapeutics to Outperform | MT |
Apr. 10 | Transcript : Chemomab Therapeutics Ltd. - Special Call |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 15.07M |
---|---|---|---|---|---|
Net income 2024 * | -15M | Net income 2025 * | -22M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-35.3
x | P/E ratio 2025 * |
-23.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 4.97% |
Latest transcript on Chemomab Therapeutics Ltd.
1 day | +11.43% | ||
1 week | +26.17% | ||
Current month | +51.23% | ||
1 month | +51.23% | ||
3 months | +60.39% | ||
6 months | +96.40% | ||
Current year | +107.57% |
Managers | Title | Age | Since |
---|---|---|---|
Adi Mor
CEO | Chief Executive Officer | 43 | 11-09-21 |
Sigal Fattal
DFI | Director of Finance/CFO | 53 | 19-12-31 |
Chief Tech/Sci/R&D Officer | 56 | 22-11-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Neil Cohen
BRD | Director/Board Member | 60 | 20-03-31 |
Nissim Darvish
CHM | Chairman | 59 | 21-03-15 |
Claude Nicaise
BRD | Director/Board Member | 71 | 21-03-15 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-30 | 1.06 | +11.58% | 220,286 |
24-05-29 | 0.95 | +4.53% | 157,692 |
24-05-28 | 0.9088 | +4.46% | 189,493 |
24-05-24 | 0.87 | +3.69% | 12,731 |
24-05-23 | 0.839 | -0.12% | 53,890 |
Delayed Quote Nasdaq, May 30, 2024 at 03:59 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+107.57% | 15.07M | |
+8.92% | 114B | |
+10.48% | 105B | |
-1.83% | 21.73B | |
-6.45% | 23.83B | |
-10.39% | 18.1B | |
-42.36% | 16.34B | |
-14.45% | 16.13B | |
+3.76% | 13.75B | |
+28.94% | 11.76B |
- Stock Market
- Equities
- CMMB Stock